Effects of gestational age at enrollment in pregnancy exposure registries

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 4, 2015, Pages 343-352

  Margulis, Andrea V ^a   Mittleman, Murray A ^a,b   Glynn, Robert J ^a,c   Holmes, Lewis B ^d   Hernández Díaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anticonvulsants; Left truncation; Major congenital malformations; Pharmacoepidemiology; Pregnancy registries; Spontaneous abortions

Indexed keywords

ANTICONVULSIVE AGENT; LAMOTRIGINE; VALPROIC ACID;

ADULT; ARTICLE; CONGENITAL MALFORMATION; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL EXPOSURE; PRENATAL SCREENING; PRIORITY JOURNAL; RISK FACTOR; SPONTANEOUS ABORTION; ABNORMALITIES, DRUG-INDUCED; CHEMICALLY INDUCED; PREGNANCY COMPLICATIONS; REGISTER; STATISTICS AND NUMERICAL DATA;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ANTICONVULSANTS; FEMALE; GESTATIONAL AGE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; REGISTRIES;

EID: 84925938341     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3731     Document Type: Article

References (31)

1. Macklin R. Enrolling pregnant women in biomedical research. Lancet 2010; 375(9715): 632-3.
2. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Reviewer Guidance: Evaluating the Risks of Drug Exposure in Human Pregnancies. 2005.
3. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency. Guideline on the Exposure to Medicinal Products during Pregnancy: Need for Post-Authorisation Data. 2005.
4. Registries for Evaluating Patient Outcomes: A User's Guide (2nd edn), Gliklich RE, Dreyer NA (eds). Agency for Healthcare Research and Quality: Rockville, MD, 2010.
5. Kennedy DL, Uhl K, Kweder SL. Pregnancy exposure registries. Drug Saf 2004; 27(4): 215-28.
6. Meador KJ, Pennell PB, Harden CL, et al. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology 2008; 71(14): 1109-17. doi:10.1212/01.wnl.0000316199.92256.af.
7. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Establishing Pregnancy Exposure Registries. 2002.
8. Howards PP, Hertz-Picciotto I, Poole C. Conditions for bias from differential left truncation. Am J Epidemiol 2007; 165(4): 444-52.
9. Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies-analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 2008; 26(1): 31-5. doi:10.1016/j.reprotox.2008.06.006.
10. Xu R, Luo Y, Chambers C. Assessing the effect of vaccine on spontaneous abortion using time-dependent covariates Cox models. Pharmacoepidemiol Drug Saf 2012; 21(8): 844-50. doi:10.1002/pds.3301.
11. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61(5): 673-8. doi:10.1001/archneur.61.5.673.
12. Holmes LB, Wyszynski DF. North American antiepileptic drug pregnancy registry. Epilepsia 2004; 45(11): 1465. doi:10.1111/j.0013-9580.2004.451102.x.
13. Tomson T, Battino D, Craig J, et al. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010; 51(5): 909-15. doi:10.1111/j.1528-1167.2010.02525.x.
14. Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol 2011; 91(9): 807-12. doi:10.1002/bdra.20842.
15. Mawer G, Briggs M, Baker GA, et al. Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study. Seizure 2010; 19(2): 112-9. doi:10.1016/j.seizure.2009.11.008.
16. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362(23): 2185-93. doi:10.1056/NEJMoa0907328.
17. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78(21): 1692-9. doi:10.1212/WNL.0b013e3182574f39.
18. Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 1999; 59(1): 1-2. doi:10.1002/(SICI)1096-9926(199901)59:1<1::AID-TERA1>3.0.CO;2-L.
19. Annegers JF, Baumgartner KB, Hauser WA, et al. Epilepsy, antiepileptic drugs, and the risk of spontaneous abortion. Epilepsia 1988; 29(4): 451-8.
20. Ammon Avalos L, Galindo C, Li DK. A systematic review to calculate background miscarriage rates using life table analysis. Birth Defects Res A Clin Mol Teratol 2012; 94(6): 417-23. doi:10.1002/bdra.23014.
21. Rothman K. Episheet: Spreadsheets for the analysis of epidemiologic data. http://www.drugepi.org/wp-content/uploads/2012/10/Episheet.xls (accessed March 17, 2011).
22. Ventura SJ, Abma JC, Mosher WD, et al. Estimated pregnancy rates by outcome for the United States, 1990-2004. Natl Vital Stat Rep 2008; 56(15): 1-25, 8.
23. Ventura SJ, Curtin SC, Abma JC, et al. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep 2012; 60(7): 1-21.
24. Vajda FJ, O'Brien T, Hitchcock A, et al. The internal control group in a register of antiepileptic drug use in pregnancy. J Clin Neurosci 2008; 15(1): 29-35. doi:10.1016/j.jocn.2006.10.015.
25. Howards PP, Hertz-Picciotto I, Bech BH, et al. Spontaneous abortion and a diet drug containing caffeine and ephedrine: a study within the Danish national birth cohort. PLoS One 2012; 7(11): e50372. doi:10.1371/journal.pone.0050372.
26. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167(4): 492-9. doi:10.1093/aje/kwm324.
27. Schisterman EF, Cole SR, Ye A, et al. Accuracy loss due to selection bias in cohort studies with left truncation. Paediatr Perinat Epidemiol 2013; 27(5): 491-502. doi:10.1111/ppe.12073.
28. Cain KC, Harlow SD, Little RJ, et al. Bias due to left truncation and left censoring in longitudinal studies of developmental and disease processes. Am J Epidemiol 2011; 173(9): 1078-84. doi:10.1093/aje/kwq481.
29. Kleinbaum D, Kupper L, Nizam A, et al. Applied Regression Analysis and Other Multivariable Methods (4th edn). Thomson Brooks/Cole, 2007. Chapter 22, Belmont, CA, USA.
30. Matok I, Azoulay L, Yin H, et al. Immortal time bias in observational studies of drug effects in pregnancy. Birth Defects Res A Clin Mol Teratol 2014. doi:10.1002/bdra.23271.
31. Charlton RA, Cunnington MC, de Vries CS, et al. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries. Drug Saf 2008; 31(1): 39-51.